Fabry disease and treatment with agalsidase alpha: Unsuspected cardiac arrhythmia in two heterozygous women: In reference to pharmacovigilance

European Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2008, Pages 635-639

  Mougenot, Philippe ^a   Lidove, Olivier ^a   Caillaud, Catherine ^b   Arnaud, Philippe ^a   Papo, Thomas ^a  

^a BICHAT HOSPITAL   (France)

^b Cochin University Hospital ^*  (France)

Author keywords

Adverse events; Agalsidase alpha; Enzyme replacement therapy; Fabry disease; Pharmacovigilance

Indexed keywords

AGALSIDASE ALFA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ARTICLE; BRADYCARDIA; CASE REPORT; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FRANCE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HETEROZYGOTE; HUMAN; NEUROPATHIC PAIN; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYNCOPE;

ADULT; ALPHA-GALACTOSIDASE; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED;

EID: 42549131987     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0460-8     Document Type: Article

References (19)

1. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733-3774
2. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750-760
3. Macdermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38(11):769-775
4. Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alpha for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345-354
5. Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75(1):65-74
6. Agence Française de Sécurité Sanitaire de Produits de Santé (2005) Bonnes pratiques de pharmacovigilance. Arrêté du 28 avril 2005. AFSSAPS, Paris
7. Gupta S, Ries M, Kotsopoulos S et al (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease. Medicine 84:261-268
8. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):347-352
9. Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J 28:1228-1235
10. Schiffmann R, Kopp JB, Austin HA 3rd (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743-2749
11. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345(1):9-16
12. Germain DP (2002) Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 11(10):1467-1476
13. Linthorst GE, Hollak CE, Donker-Koopman WE et al (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589-1595
14. Whitfield PD, Calvin J, Hogg S et al (2005) Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis 28(1):21-33
15. Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alpha treatment. Eur J Clin Invest 34(12):838-844
16. Breunig F, Weidemann F, Strotmann J et al (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216-1221
17. Baehner F, Kampmann C, Whybra C (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26(7):617-627
18. Garman RD, Munroe K, Richards SM (2004) Methotrexate reduces antibody responses to recombinant human alpha-galactosidase. A therapy in a mouse model of Fabry disease. Clin Exp Immunol 137:496-502
19. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long term stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547-1557